MolecularHealth Continues to Grow Management Team with New Chief Commercial Officer

  MolecularHealth Continues to Grow Management Team with New Chief Commercial

Laura Housman joins MolecularHealth’s executive leadership, bringing expertise
in strategic marketing and product management

Business Wire

THE WOODLANDS, Texas -- October 8, 2013

As MolecularHealth moves towards the commercialization of its automated
genetic diagnostic platform for cancer care in the first quarter of 2014, the
company announced that it has hired Laura Housman to serve as its chief
commercial officer. This new hire follows the recent announcement of five key
members of the company’s executive team, veterans of US Oncology and Oncopath

Housman comes to MolecularHealth with more than 20 years of marketing and
sales experience, largely focused in the healthcare and biotech industries.
Most recently, she served as Vice President of Global Market Access, Pricing
and Health Economics at Novartis Pharmaceuticals’ Molecular Diagnostics (MDx)
and Genoptix. She earned both her Master of Business Administration and Master
of Public Health degrees from Boston University.

“Laura has an impressive track record of introducing healthcare products and
services to the market. Her experience at Novartis MDx, Genoptix and Genzyme
Genetics gives her great insight into the molecular diagnostics space, which
will be essential as we bring MolecularHealth’s platform to market in 2014,”
said Lloyd Everson, M.D., CEO of MolecularHealth. “Laura’s background made her
a perfect addition to the executive team and we’re thrilled to have her on

“After having worked in the molecular diagnostics industry for years and
viewing it from multiple angles, I truly believe the notion of having
analytics as the engine to drive decision making for doctors and patients is
key,” said Laura Housman. “There is a high unmet patient need, and I’m excited
to come on board at such a formative time and be given the chance to shape
this offering and help the MolecularHealth team meet that need.”

After eight years of development by a multidisciplinary team of doctors,
scientists and IT experts in Heidelberg, Germany, MolecularHealth is preparing
for the commercial launch of its genetic diagnostic platform. The company,
backed by Dietmar Hopp, co-founder and former chairman and CEO of SAP, offers
an end-to-end service that walks patients and their healthcare providers
through the molecular diagnostic process—collecting tumor samples, analyzing
the samples, and interpreting the results using a unique analytics
platform—all to generate safer and more targeted cancer treatment choices. As
part of its offering, MolecularHealth will provide patients, oncologists and
pathologists with complete logistical support and help navigating insurance
reimbursement for recommended treatments.


MolecularHealth delivers on the promise of personalized, precision medicine.
By using advanced proprietary information technologies to sift through
terabytes of genetic and molecular test findings in a fraction of the time
needed for current manual analysis, MolecularHealth provides doctors and
patients with faster, more accurate insights into the role genes play in the
progression and treatment of an individual’s cancer. Eight years in
development by a multidisciplinary team of doctors, scientists and IT experts,
MolecularHealth works in partnership with some of the world’s leading
healthcare and information technology companies, including the University of
Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug
Administration (FDA). The company has headquarters in The Woodlands, Texas;
Basel, Switzerland; and Heidelberg, Germany. Visitwww.molecularhealth.comfor
more information.


Gregory FCA
Jessica Attanasio
Associate Vice President
Press spacebar to pause and continue. Press esc to stop.